New York State Common Retirement Fund Buys 4,765 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

New York State Common Retirement Fund increased its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 9.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 54,492 shares of the company’s stock after acquiring an additional 4,765 shares during the quarter. New York State Common Retirement Fund’s holdings in Intellia Therapeutics were worth $1,661,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Blue Trust Inc. bought a new position in Intellia Therapeutics in the 4th quarter worth about $26,000. Signaturefd LLC raised its stake in Intellia Therapeutics by 89.3% in the fourth quarter. Signaturefd LLC now owns 1,592 shares of the company’s stock valued at $49,000 after purchasing an additional 751 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Intellia Therapeutics by 95.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,263 shares of the company’s stock valued at $72,000 after purchasing an additional 1,108 shares during the last quarter. Daiwa Securities Group Inc. grew its stake in Intellia Therapeutics by 35.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company’s stock worth $93,000 after buying an additional 793 shares in the last quarter. Finally, Pathstone Family Office LLC increased its holdings in shares of Intellia Therapeutics by 20.3% in the 3rd quarter. Pathstone Family Office LLC now owns 6,438 shares of the company’s stock worth $204,000 after buying an additional 1,086 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, EVP James Basta sold 2,297 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $32.99, for a total value of $75,778.03. Following the completion of the sale, the executive vice president now owns 81,571 shares in the company, valued at approximately $2,691,027.29. The transaction was disclosed in a document filed with the SEC, which is available at this link. 3.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

NTLA has been the subject of several research reports. Wedbush reiterated a “neutral” rating and issued a $29.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, April 23rd. Wolfe Research began coverage on Intellia Therapeutics in a report on Thursday, February 15th. They issued a “peer perform” rating for the company. The Goldman Sachs Group cut Intellia Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $136.00 to $32.00 in a report on Friday, February 23rd. Finally, Canaccord Genuity Group upped their target price on Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $67.00.

Intellia Therapeutics Stock Performance

Shares of Intellia Therapeutics stock opened at $24.86 on Friday. The company’s 50 day moving average price is $25.50 and its 200-day moving average price is $27.20. Intellia Therapeutics, Inc. has a 52-week low of $19.37 and a 52-week high of $47.48. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of -4.60 and a beta of 1.85.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. The business had revenue of ($1.92) million for the quarter, compared to analyst estimates of $15.10 million. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. During the same quarter last year, the firm earned ($1.40) EPS. As a group, equities research analysts forecast that Intellia Therapeutics, Inc. will post -5.57 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.